Introduction {#sec1}
============

Liver cancer is the second leading cause of death worldwide, accounting for 745,000 deaths in 2012,[@bib1] and the fifth cause of cancer-related deaths in Japan.[@bib2] According to the Japanese National vital statistics, a total of 40,099 persons (19,208 men and 20,891 women) died of liver cancer in 2014.[@bib2] Also, data from the population-based cancer registries in Japan indicate that 43,677 persons (28,623 men and 15,054 women) were diagnosed with liver cancer in 2012.[@bib3]

The most prevalent type of primary liver cancer is hepatocellular carcinoma (HCC),[@bib4] accounting for 94% of liver cancers in Japan.[@bib5] Although hepatitis B viral (HBV) infection is a predominant cause of HCC in many Asian countries such as China, South Korea, Singapore, Thailand, Malaysia, India, the Philippines, and Taiwan, the main cause of HCC in Japan is hepatitis C viral (HCV) infection,[@bib6] accounting for approximately 70% of cases of HCC. However, the importance of the chronic liver diseases nonalcoholic fatty liver disease (NAFLD) and nonalcoholic liver steatohepatitis (NASH) as risk factors for HCC has recently increased.[@bib7]

The BioBank Japan (BBJ) project is a large patient-oriented cohort consisting of more than 200,000 patients with 51 diseases, and DNA and serum samples and clinical information can be used for further studies. In this report, we aimed to provide an overview of the patients with liver cancer in the BBJ project.

Materials and methods {#sec2}
=====================

Study population {#sec2.1}
----------------

The BBJ project was established in 2003.[@bib8], [@bib9], [@bib10], [@bib11], [@bib12] Briefly, we enrolled 199,982 participants with 47 diseases from 12 medical institutes consisting of 67 hospitals in Japan between the fiscal years 2003 and 2007. Written informed consent was obtained from all participants. The study protocol of the BBJ project was approved by the Research Ethics Committees of the Institute of Medical Science, the University of Tokyo, RIKEN Yokohama Institute, and 12 cooperating hospitals. Clinical information for participants with liver cancer (n = 1733; 1316 men, 417 women) was used in this analysis.

Data collection {#sec2.2}
---------------

Information about smoking habits (never, former, current smoker of \<20 pack years, current smoker of ≥20 pack years, current smoker of unknown pack years, or unknown), alcohol consumption habits (never, former, current drinker of \<15 g/day, current drinker of 15--29 g/day, current drinker of ≥30 g/day, or unknown), height, weight, physical activity frequency (none, 1--2 times/week, ≥3 times/week, or unknown), family history of liver cancer (yes, no/unknown), and medical history of HBV or HCV infection (yes, no/unknown) was obtained through medical records and interviews using a standardized questionnaire at the time of enrollment.[@bib9], [@bib10], [@bib11], [@bib12] Body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters and categorized as \<18.5 kg/m^2^, 18.5--24.9 kg/m^2^, 25.0--29.9 kg/m^2^, ≥30 kg/m^2^, or unknown.

Birth year; sex; time to entry in this cohort, from the diagnosis of liver cancer; age at entry in this cohort; liver cancer histology; laboratory examinations such as blood chemical markers including serum carcinoembryonic antigen (CEA; \<5 ng/mL, 5--9 ng/mL, ≥10 ng/mL, or unknown), carbohydrate antigen 19-9 (CA 19-9; \<37 U/mL, 37--99 U/mL, ≥100 U/mL, or unknown), and alpha-fetoprotein (AFP; \<10 U/mL, 10--99 U/mL, ≥100 U/mL, or unknown) levels; and imaging data were collected from medical records. Liver cancer histology was based on tissue obtained at biopsy or cytological samples, and missing data for histological types were complemented by data from tissue samples. Liver cancer stage was categorized according to the Japanese Classification of Liver Cancer, the Fourth (2000) and Fifth (2008) Editions (stage I, II, III, IV, or unknown). Pathologic stage was primarily used for classification, and missing data for pathologic stage were complemented with clinical stage results.

Follow-up {#sec2.3}
---------

The follow-up survival survey was implemented from 2010 to 2014 to collect patient vital status, and the data were coded according to the 10th revision of the International Classification of Disease.

Statistical analysis {#sec2.4}
--------------------

Sex-specific statistical analyses were conducted. First, we described the distribution of time from the initial diagnosis of prostate cancer to entry into the study cohort. Second, we drew an age-specific distribution of the patients with liver cancer and compared that with the Patient Survey in Japan, 2005.[@bib13] We report the liver cancer histology, patient characteristics, patient clinical characteristics, liver cancer stage, and causes of death. Third, we calculated the cumulative and relative survival rates of liver cancer. We calculated the cumulative survival rate using the Kaplan--Meier method. We limited the survival rate calculation to patients who entered the cohort ≤90 days from the diagnosis of liver cancer. To calculate the expected survival rates, we obtained the survival rate table for the reference cohort from the Cancer Registry and Statistics, Cancer Information Service, National Cancer Center, Japan.[@bib14] The survival rate table was based on sex- and age-specific mortality rates and Gompertz--Makeham\'s Law in Abridged Life Tables, published annually by the Statistics and Information Department of Ministry of Health, Labor and Welfare, Japan. The relative survival rates were calculated by dividing the cumulative survival rates by age-adjusted expected survival rates. All statistical analyses were performed using SAS software (version 9.4; SAS Institute Inc., Cary, NC, USA).

Results {#sec3}
=======

The distribution of time from the initial diagnosis of liver cancer to entry into the study cohort is displayed in [Fig. 1](#fig1){ref-type="fig"}. The proportion of patients who enrolled \<1, 1, and 2 years after the initial diagnosis of liver cancer were 34.6%, 21.1%, 11.1%, and 33.2% in men and 34.1%, 22.1%, 14.4%, and 29.4% in women, respectively. The mean ± standard deviation age of the patients was 68.0 ± 8.5 (range, 32--92) years ([Fig. 2](#fig2){ref-type="fig"}). Patients in this study appeared to be slightly younger than patients in the national survey in Japan.[@bib13]

Of the 1354 patients with information on the histology of liver cancer, 91.9% had HCC, and 3.7% had intrahepatic cholangiocarcinoma ([Table 1](#tbl1){ref-type="table"}). Of all the included patients, 20.1% of men and 25.6% of women were obese; 31.4% of men and 9.1% of women were current alcohol drinkers; 25.6% of men and 8.4% of women were current smokers; and 79.1% of men and 76.4% of women were not habitually physically active ([Table 2](#tbl2){ref-type="table"}). About 9.0% of men and 10.1% of women had a family history of liver cancer. Of the information we obtained, normal CEA, CA 19-9, and AFP levels were present in 75.2%, 70.8%, and 70.2% of men, respectively, and 71.5%, 61.2%, and 60.2% of women, respectively. About 11.7% of men and 5.8% of women had a medical history of HBV infection, and 43.8% of men and 52.8% of women had a medical history of HCV infection. The clinical stage of liver cancer was not identified for almost all participants (99.8%).

[Table 3](#tbl3){ref-type="table"} shows the causes of death due to liver cancer among the patients who entered the cohort ≤90 days from the diagnosis of liver cancer. The mortality rate during the study period was about 75% for men and 73% for women. Cancer-related mortality occurred for 65% of the men and 68% of the women who died, and the remaining patients died because of hepatic failure (0.5% of men), rupture of esophageal varices (0.5% of men), or other reasons. The 3-, 5-, and 10-year cumulative survival rates were 57%, 47%, and 25% in men, respectively, and 49%, 41%, and 27% in women, respectively ([Fig. 3](#fig3){ref-type="fig"}). The 5- and 10-year relative survival rates were 53% and 34% in men, respectively, and 47% and 38% in women, respectively.

Discussion {#sec4}
==========

The results of the present study provide an overview of the patients with liver cancer in the BBJ project, which is a large patient-based biobank. A strength of this cohort study is its prospective design with a large number of patients who were recruited from hospitals located nationwide in Japan.

The histology of liver cancer was not available for 61% of the patients because current guidelines for liver cancer from the Japan Society of Hepatology[@bib15] indicate that only the use of imaging results in an accurate diagnosis of HCC. The most prevalent type (91.9%) of primary liver cancer was HCC, similar to the reported 94% in Japan.[@bib5] Therefore, HCC might have been present for a large proportion of the patients without identified histology.

Japan is the only Asian country with a predominance of HCV-related HCC[@bib6]; approximately 70% and 16% of HCC cases were caused by HCV and HBV infection, respectively. In our analysis, 44% and 12% of men and 53% and 8% of women had a medical history of HCV and HBV infection, respectively. The lower prevalence of HBV or HCV intention might have resulted from misclassification because we obtained the medical history of HCV/HBV infection only when the patients experienced. There are several risk factors for liver cancer other than infections, such as NASH, which is associated with obesity,[@bib16] habitual alcohol consumption,[@bib17] and smoking.[@bib18] According to the National Health and Nutrition Examination Survey in Japan,[@bib19] 28% of men and 22% of women are obese (BMI ≥25.0 kg/m^2^), 5% of men and 9% of women reportedly currently drink alcohol, and 47% of men and 11% of women are current smokers. Compared with the National Health and Nutrition Examination Survey, a greater proportion of the male patients in the present study were daily alcohol consumers, and a greater proportion of women was overweight/obesity. Since the number of people with HCV infection is gradually decreasing in Japan,[@bib20] these lifestyle choices might have resulted in the lower prevalence of HBV and HCV infections.

The Japanese Association of Clinical Cancer Centers reported that the 5- and 10-year relative survival rates for liver cancer were 34.8% and 15.3%, respectively.[@bib21] The relative survival rates in the present study were much higher. However, because the data regarding factors that affect survival rate, such as stage, surgery,[@bib22], [@bib23], [@bib24] or chemotherapy[@bib25], [@bib26] were missing, the results may have been biased.

Conclusion {#sec5}
==========

The present study provides an overview of the patients with liver cancer in the BBJ project. We are planning further analyses combined with various high-throughput 'omics' technologies using DNA and serum samples from the BBJ project. However, the interpretation of the forthcoming results may require careful consideration because of the missing data of not only newly diagnosed cases but also prevalent cases.
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###### 

Histology of liver cancer.

Table 1

  Diagnosis                         Men (n = 1316)   Women (n = 417)   Total (n = 1733)   \%
  --------------------------------- ---------------- ----------------- ------------------ ------
  Hepatocellular carcinoma          503              119               622                91.9
  Intrahepatic cholangiocarcinoma   16               9                 25                 3.7
  Combined                          5                1                 6                  0.9
  Cholangiolocellular carcinoma     0                0                 0                  0
  Cystadenocarcinoma                0                1                 1                  0.1
  Hepatoblastoma                    0                0                 0                  0
  Undifferentiated carcinoma        0                0                 0                  0
  Others                            6                3                 9                  1.3
  Unknown                           12               2                 14                 2.1
  Missing                           744              282               1056               --

Combined, combined hepatocellular and intrahepatic cholangiocarcinoma.

###### 

Characteristics of the study participants with liver cancer.

Table 2

  Variable                             Categorization    Men (n = 1316)   Women (n = 417)                        
  ------------------------------------ ----------------- ---------------- ----------------- ------ ------ ------ ------
  **Body mass index** (kg/m^2^)                                                                                  
                                       \<18.5            144              10.9              11.1   47     11.3   11.9
  18.5--24.9                           892               67.8             68.8              246    59.0   62.4   
  25.0--29.9                           228               17.3             17.6              77     18.5   19.5   
  ≥30                                  32                2.4              2.5               24     5.8    6.1    
  Unknown                              50                3.8              --                23     5.5    --     
  **Drinking status**                                                                                            
  Never                                                  309              23.5              23.5   309    74.1   74.1
  Former                                                 450              34.2              34.2   46     11.0   11.0
  Current (g/day)                      \<15              163              12.4              12.4   27     6.5    6.5
  15--29                               77                5.9              5.9               5      1.2    1.2    
  ≥30                                  173               13.1             13.1              6      1.4    1.4    
  Unknown                                                144              10.9              --     24     5.8    --
  **Smoking status**                                                                                             
  Never                                                  261              19.8              22.1   310    74.3   78.7
  Former                                                 582              44.2              49.2   45     10.8   11.4
  Current                              \<20 pack years   75               5.7               6.3    15     3.6    3.8
  ≥20 pack years                       228               17.3             19.3              18     4.3    4.6    
  Unknown                              37                2.8              3.1               6      1.4    1.5    
  Unknown                                                133              10.1              --     23     5.5    --
  **Physical activity** (times/week)                                                                             
                                       ≥3                197              15.0              18.1   71     17.0   20.9
  1--2                                 31                2.4              2.8               9      2.2    2.7    
  Not habitually                       863               65.6             79.1              259    62.1   76.4   
  Unknown                              225               17.1             --                78     18.7   --     
  **Had a family history of**                                                                                    
  Liver cancer                         Yes               118              9.0               --     42     10.1   --
  No/Unknown                           1198              91.0             --                375    89.9   --     

  Variable                       Code   Men (n = 1316)   Women (n = 417)                        
  ------------------------------ ------ ---------------- ----------------- ------ ------ ------ ------
  CEA (ng/mL)                    \<5    464              35.3              75.2   133    31.9   71.5
  5--9                           92     7.0              14.9              31     7.4    16.7   
  ≥10                            61     4.6              9.9               22     5.3    11.8   
  Unknown                        699    53.1             --                231    55.4   --     
  CA 19-9 (U/mL)                 \<37   359              27.3              70.8   93     22.3   61.2
  37--99                         103    7.8              20.3              38     9.1    25.0   
  ≥100                           45     3.4              8.9               21     5.0    13.8   
  Unknown                        809    61.5             --                265    63.5   --     
  AFP (U/mL)                     \<10   758              57.6              70.2   194    46.5   60.2
  10--99                         106    8.1              9.8               39     9.4    12.1   
  ≥100                           216    16.4             20.0              89     21.3   27.6   
  Unknown                        236    17.9             --                95     22.8   --     
  **Had a medical history of**                                                                  
   Hepatitis B                   Yes    154              11.7              --     24     5.8    --
   Hepatitis C                   Yes    577              43.8              --     220    52.8   --

CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9; AFP, alpha-fetoprotein.

###### 

Causes of death for patients who entered the cohort ≤90 days from the diagnosis of liver cancer.

Table 3

                                   Men (n = 311)   Women (n = 88)                      
  -------------------------------- --------------- ---------------- ------ ---- ------ ------
  **Alive**                        108             34.7                    28   31.8   
  **Total deaths**                 203             65.3                    60   68.2   
   Cancer-related                  148                              72.9   48          80.0
   Hepatic failure                 1                                0.5    0           --
   Rupture of esophageal varices   1                                0.5    0           --
   Other causes                    25                               12.3   8           13.3
   Unknown                         28                               13.8   4           6.7

[^1]: BioBank Japan Cooperative Hospital Group are listed in [Appendix](#appsec1){ref-type="sec"}.
